Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionImmunocytokine generated via the dock and lock (DNL) that consists of 4 molecules of interferon (IFN) alpha-2b fused to IMMU-114, a humanized mAb against HLA-DR
Molecular Target Major histocompatibility complex class II DR (HLA-DR)
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard IndicationHematologic malignancies
Indication DetailsTreat hematologic malignancies
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today